NCT04093622View on ClinicalTrials.gov

Long-term Follow-Up Study Following Treatment With Fate Therapeutics' Engineered Cellular Immunotherapy

TerminatedOBSERVATIONAL
Enrollment

2

Participants

Timeline

Start Date

October 4, 2019

Primary Completion Date

April 9, 2020

Study Completion Date

April 9, 2020

Conditions
Hematological Malignancy
Interventions
GENETIC

Genetically engineered NK cells

No study drug is administered in this study. Subjects who received lentivirus-mediated genetically engineered NK Cells in a previous trial will be evaluated in this trial for long-term safety and efficacy.

Trial Locations (5)

55455

University of Minnesota Masonic Cancer Center, Minneapolis

77030

MD Anderson Cancer Center, Houston

85054

Mayo Clinic, Phoenix

92037

UC San Diego, San Diego

98104

Swedish Cancer Institute, Seattle

Sponsors

Lead Sponsor

Fate Therapeutics
All Listed Sponsors
lead

Fate Therapeutics

INDUSTRY

NCT04093622 - Long-term Follow-Up Study Following Treatment With Fate Therapeutics' Engineered Cellular Immunotherapy | Biotech Hunter | Biotech Hunter